🔎 Trials Near Me

Почетна › Akutna mijeloidna leukemija › Тексас › Houston

Kliničke studije za Akutna mijeloidna leukemija u gradu Houston, TX

88 studija za Akutna mijeloidna leukemija traži učesnike na lokacijama u gradu Houston i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.

Zvanični tekst studije (na engleskom)

Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →

CD70.CAR for AML and Other CD70+ Leukemias

Тражи се учесникФаза 1
  • Texas Children's Hospital, Houston
  • The Methodist Hospital, Houston
До 75 година · Оба пола · Ажурирано 13. 11. 2026. · NCT06345027

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Тражи се учесникФаза 2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06317649

Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia

Тражи се учесникФаза 1
  • UT MD Anderson, Houston
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07549464

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Тражи се учесникФаза 1/2
  • M D Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04774393

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Тражи се учесникФаза 2
  • M D Anderson Cancer Center, Houston
Узраст од 18 до 65 · Оба пола · Ажурирано 12. 11. 2026. · NCT02115295

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Тражи се учесникФаза 3
  • University of Texas, Houston
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07007312

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Тражи се учесникФаза 2
  • M D Anderson Cancer Center, Houston
Узраст 12 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT03589729

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
  • UT MD Anderson Cancer Center, Houston
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Тражи се учесникФаза 3
  • Houston Methodist Cancer Center, Houston
  • MD Anderson Cancer Center, Houston
  • The University of Texas Health Science Center at Houston, Houston
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06852222

Personalized NK Cell Therapy in CBT

Тражи се учесникФаза 2
  • M D Anderson Cancer Center, Houston
Узраст од 15 до 80 · Оба пола · Ажурирано 2. 11. 2026. · NCT02727803

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Тражи се учесникФаза 2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT05564390

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Тражи се учесникФаза 1/2
  • M D Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT03214562

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

Тражи се учесникОпсервациона студија
  • MD Anderson Cancer Center, Houston
Сви узрасти · Оба пола · Ажурирано 30. 10. 2026. · NCT06906380

Study of REM-422 in Patients With AML or Higher Risk MDS

Тражи се учесникФаза 1
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06297941

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Тражи се учесникОпсервациона студија
  • Texas Children's Hospital, Houston
Узраст од 0 до 38 · Оба пола · Ажурирано 29. 10. 2026. · NCT06131801

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Тражи се учесникФаза 1/2
  • MD Anderson, Houston
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT05143996

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Тражи се учесникФаза 2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
Узраст од 18 до 59 · Оба пола · Ажурирано 28. 10. 2026. · NCT05554393

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Тражи се учесникФаза 1/2
  • Research Site, Houston
Узраст 16 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07155226

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

Тражи се учесникФаза 1/2
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT06969430

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Тражи се учесникФаза 1
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
До 21 година · Оба пола · Ажурирано 23. 10. 2026. · NCT07012044

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Тражи се учесникФаза 2/3
  • The University of Texas MD Anderson Cancer Center /ID# 279402, Houston
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07581002

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

Тражи се учесникФаза 1
  • The University of Texas MD Anderson Cancer Center, Houston
Узраст од 18 до 85 · Оба пола · Ажурирано 21. 10. 2026. · NCT06834282

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

Тражи се учесникФаза 3
  • Clinical Trial Site, Houston
Узраст 12 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT07211958

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS

Тражи се учесникФаза 1
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT06533761

A Study of Revumenib and Mezigdomide in People With Leukemia

Тражи се учесникФаза 1/2
  • MD Anderson Cancer Center (Data Collection Only), Houston
Узраст 12 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT07356154

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Тражи се учесникФаза 1
  • University of Texas MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT06846606

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Тражи се учесникФаза 1Здраве особе су добродошле
  • M.D. Anderson Cancer Center, Department of Leukemia, Houston
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT05986240

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Тражи се учесникФаза 1
  • M D Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT02390635

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Тражи се учесникФаза 1
  • M D Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT05010772

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

Тражи се учесникФаза 1
  • The University of Texas MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT06616636

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Тражи се учесникФаза 2
  • Houston Methodist Neal Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07060001

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Тражи се учесникФаза 2/3
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT04256317

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Тражи се учесникФаза 1/2
  • M D Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT04140487

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

Тражи се учесникФаза 2
  • The University of Texas M. D. Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT06811233

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Тражи се учесникФаза 2
  • M D Anderson Cancer Center, Houston
Узраст 50 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT03586609

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Тражи се учесникФаза 1
  • University of Texas MD Anderson Cancer Center, Houston
Узраст од 12 до 78 · Оба пола · Ажурирано 29. 9. 2026. · NCT03802695

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

Тражи се учесникФаза 2
  • M D Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT03629171

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Тражи се учесникФаза 1/2
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT06548230

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Тражи се учесникФаза 1/2Здраве особе су добродошле
  • M D Anderson Cancer Center, Houston
Узраст 12 и старији · Оба пола · Ажурирано 23. 9. 2026. · NCT05360160

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

Тражи се учесникФаза 1
  • M D Anderson Cancer Center, Houston
Узраст 1 и старији · Оба пола · Ажурирано 18. 9. 2026. · NCT03630991

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

Тражи се учесникФаза 1
  • The University of Texas M. D. Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 18. 9. 2026. · NCT06769490

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Тражи се учесникФаза 1/2
  • MD Anderson Cancer Center, Houston
Узраст 12 и старији · Оба пола · Ажурирано 18. 9. 2026. · NCT06284486

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Тражи се учесникФаза 3
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • UT MD Anderson Cancer Center, Houston
6 Months – 21 Years · Оба пола · Ажурирано 17. 9. 2026. · NCT04293562

Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

Тражи се учесникФаза 1
  • MD Anderson, Houston
Узраст 12 и старији · Оба пола · Ажурирано 17. 9. 2026. · NCT06786533

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Тражи се учесникФаза 2
  • The Methodist Hospital Research Institute, Houston
  • The University of Texas MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT06824168

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Тражи се учесникФаза 2
  • The University of Texas MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 15. 9. 2026. · NCT04996875

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Тражи се учесникФаза 1/2
  • M D Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 14. 9. 2026. · NCT03471260

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Тражи се учесникФаза 2
  • M D Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 14. 9. 2026. · NCT03683433

A Study of BGB-11417 in Participants With Myeloid Malignancies

Тражи се учесникФаза 1/2
  • Md Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 14. 9. 2026. · NCT04771130

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Тражи се учесникФаза 1/2
  • M D Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 4. 9. 2026. · NCT05010122

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Тражи се учесникФаза 2
  • M D Anderson Cancer Center, Houston
Узраст 12 и старији · Оба пола · Ажурирано 4. 9. 2026. · NCT03383575

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Тражи се учесникФаза 1/2
  • MD Anderson, Houston
Узраст 12 и старији · Оба пола · Ажурирано 3. 9. 2026. · NCT04588922

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Тражи се учесникФаза 2
  • M D Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 25. 8. 2026. · NCT04493164

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Тражи се учесникФаза 1/2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • UT MD Anderson Cancer Center, Houston
До 22 година · Оба пола · Ажурирано 25. 8. 2026. · NCT04726241

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Тражи се учесникРана фаза 1
  • Texas Children's Cancer and Hematology Center, Houston
1 Month – 30 Years · Оба пола · Ажурирано 24. 8. 2026. · NCT07059975

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Тражи се учесникФаза 1
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 20. 8. 2026. · NCT06001788

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Тражи се учесникФаза 2/3Здраве особе су добродошле
  • M D Anderson Cancer Center, Houston
Узраст од 18 до 70 · Оба пола · Ажурирано 11. 8. 2026. · NCT04708054

Phase I Study of HC-7366 for Acute Myeloid Leukemia

Тражи се учесникФаза 1
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 10. 8. 2026. · NCT06285890

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Тражи се учесникФаза 1/2
  • M D Anderson Cancer Center, Houston
Узраст од 12 до 80 · Оба пола · Ажурирано 7. 8. 2026. · NCT05092451

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Тражи се учесникФаза 2
  • University of Texas MD Anderson Cancer Center, Houston
Узраст 60 и старији · Оба пола · Ажурирано 16. 7. 2026. · NCT01515527

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Тражи се учесникОпсервациона студија
  • M.D. Anderson Cancer Center, Houston
  • Texas Children's Hospital - Baylor Medical Center, Houston
Сви узрасти · Оба пола · Ажурирано 6. 7. 2026. · NCT01351545

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Тражи се учесникФаза 1
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 17. 6. 2026. · NCT03113643

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Тражи се учесникФаза 1
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 15. 6. 2026. · NCT02074839

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Тражи се учесникФаза 1
  • The University of Texas MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 15. 6. 2026. · NCT05768932

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Тражи се учесникФаза 1
  • MD Anderson Cancer Center, Houston
Узраст од 3 до 21 · Оба пола · Ажурирано 12. 6. 2026. · NCT06448013

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Тражи се учесникФаза 1/2
  • M D Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 12. 6. 2026. · NCT04047641

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Тражи се учесникФаза 1
  • M.D. Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 12. 6. 2026. · NCT05834244

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Тражи се учесникФаза 1
  • MD Anderson, Houston
Узраст 18 и старији · Оба пола · Ажурирано 28. 5. 2026. · NCT04953897

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Тражи се учесникФаза 1
  • MD Anderson, Houston
Узраст 18 и старији · Оба пола · Ажурирано 28. 5. 2026. · NCT04953910

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Тражи се учесникФаза 1
  • MD Anderson Cancer Center, Houston
Узраст 13 и старији · Оба пола · Ажурирано 5. 5. 2026. · NCT04771572

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Тражи се учесникФаза 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 13. 4. 2026. · NCT05732103

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

Тражи се учесникФаза 1
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 25. 3. 2026. · NCT07107126

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Тражи се учесникФаза 1/2
  • MDACC, Houston
Узраст 12 и старији · Оба пола · Ажурирано 24. 3. 2026. · NCT04988555

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Тражи се учесникФаза 2
  • MD Anderson, Houston
Узраст од 18 до 66 · Оба пола · Ажурирано 17. 3. 2026. · NCT06859424

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Тражи се учесникФаза 1
  • MD Anderson Cancer Center, Houston
Узраст 12 и старији · Оба пола · Ажурирано 16. 3. 2026. · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Тражи се учесникФаза 1
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 13. 3. 2026. · NCT05735184

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Тражи се учесникФаза 1
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 9. 2. 2026. · NCT06950034

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Тражи се учесникФаза 1/2
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 10. 12. 2025. · NCT06680752

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

Тражи се учесникФаза 1
  • The University of Texas MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 31. 10. 2025. · NCT06549790

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Тражи се учесникФаза 1/2
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 2. 10. 2025. · NCT05211570

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Тражи се учесникФаза 1
  • The University of Texas M.D. Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 24. 9. 2025. · NCT06501196

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Тражи се учесникФаза 1
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 11. 5. 2025. · NCT06634394

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Тражи се учесникФаза 1
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 10. 3. 2025. · NCT05190471

Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia

Тражи се учесникФаза 1
  • MD Anderson Cancer Centre, Houston
Узраст 18 и старији · Оба пола · Ажурирано 10. 3. 2025. · NCT06613217

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Тражи се учесникФаза 2
  • University of Texas M.D. Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 7. 3. 2025. · NCT02781883

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Тражи се учесникФаза 1
  • MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 15. 11. 2024. · NCT06034275

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Тражи се учесникФаза 1
  • The University of Texas MD Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 20. 3. 2024. · NCT04243785

Studije za Akutna mijeloidna leukemija u drugim gradovima

Ostale studije u gradu Houston

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.